You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
共研新药向FDA启动生物制品许可申请 中生(01177.HK)与康方(09926.HK)股价齐升
阿思达克 05-24 14:14
中生制药(01177.HK)与康方生物(09926.HK)共同研发用於三线治疗转移性鼻咽癌新药已向FDA启动生物制品许可申请,两股价延续上周五升势,前者续升4.6%报9.17元创逾三个月,为表现第二强蓝筹;後者股价升破2月所创上市高位62.2元,最高见62.75元,现造62.5元,续涨9.6%,成交分别增至9,541万股及770万股。

中生制药公布,由集团与康方生物共同开发抗PD-1单抗药物「派安普利」(研发代号:AK105)已向美国食品药品监督管理局(FDA)启动提交生物制品许可申请,寻求上市批准用於三线治疗转移性鼻咽癌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account